

## AMENDMENTS TO THE CLAIMS

1. (Previously Presented) An N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium 2 methanesulfonic acid salt.
2. (Previously Presented) A method of preparing an N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium 2 methanesulfonic acid salt, comprising reacting N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium and methanesulfonic acid in an inert solvent.
3. (Currently Amended) A pharmaceutical composition for ~~preventing and treating~~ osteoporosis, comprising an osteoporosis treating effective amount of N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium 2 methanesulfonic acid salt and a pharmaceutically active carrier.
4. (Currently Amended) A pharmaceutical composition for treating bone fractures, comprising an a bone fracture treating effective amount of N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium 2 methanesulfonic acid salt and a pharmaceutically active carrier.
5. (Currently Amended) A pharmaceutical composition for ~~preventing and treating~~ allergic inflammatory diseases, comprising an allergic inflammatory disease treating effective amount of N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium 2 methanesulfonic acid salt and a pharmaceutically active carrier.
6. (Previously Presented) An oral formulation comprising an N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy] pentoxy}-benzamidinium 2 methanesulfonic acid salt, along with (a) a carbonate selected from the group consisting of alkali metal carbonate, alkali metal bicarbonate and alkaline earth metal carbonate; (b) a disintegrant selected from the group consisting of sodium starch glycolate, calcium carmellose and sodium croscarmellose; or a combination of (a) and (b).

7. (Previously Presented) The oral formulation as set forth in claim 6, further comprising an inorganic excipient.
8. (Previously Presented) The oral formulation as set forth in claim 7, wherein the inorganic excipient is calcium biphosphate, calcium phosphate, heavy magnesium oxide, precipitated calcium carbonate, magnesium carbonate, or a mixture thereof.
9. (Previously Presented) The oral formulation as set forth in any of claims 6 to 8, wherein the carbonate is sodium bicarbonate or calcium carbonate, and the disintegrant is sodium starch glycolate or sodium croscarmellose.